Targeting TP53 pathologic variants for cancer immunotherapy using a self-replicating mRNA vaccine strategy. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results